<?xml version="1.0" encoding="UTF-8"?>
<p id="Par101">Generation of human antibodies by transgenic animals has been accomplished by seven companies: Abgenix, XenoMouse (purchased by Amgen in 2005); Medarex, HuMAbMouse (purchased by Bristol Myers Squibb in 2009); Ligand, OmniRat; Kymab, KyMouse; Regeneron VelocImmune mouse; and the more recent Harbour Antibodies, H2L2 Mouse and Trianni Inc., Trianni Mouse [
 <xref ref-type="bibr" rid="CR162">162</xref>, 
 <xref ref-type="bibr" rid="CR165">165</xref>] (Table 
 <xref rid="Tab4" ref-type="table">4</xref>). The first antibody drug derived from transgenic mice was approved by the US FDA in 2006 [
 <xref ref-type="bibr" rid="CR177">177</xref>], and as of 2019, 19 transgenic animal-derived antibody drugs [
 <xref ref-type="bibr" rid="CR17">17</xref>â€“
 <xref ref-type="bibr" rid="CR34">34</xref>, 
 <xref ref-type="bibr" rid="CR177">177</xref>] generated by Xenomouse, HuMabMouse, and VelocImmune mouse are on the market (Table 
 <xref rid="Tab5" ref-type="table">5</xref>). Eight of the drugs are used for cancer treatment, while the others are for autoimmune or inflammatory diseases. 
</p>
